These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

339 related articles for article (PubMed ID: 27994475)

  • 21. The 'cephalosporin era' of triazole therapy: isavuconazole, a welcomed newcomer for the treatment of invasive fungal infections.
    Chitasombat MN; Kontoyiannis DP
    Expert Opin Pharmacother; 2015; 16(10):1543-58. PubMed ID: 26100603
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Efficacy and safety of Isavuconazole for the treatment of invasive
    Sivasubramanian G; Chandrasekar PH
    Expert Opin Pharmacother; 2022 Apr; 23(5):543-549. PubMed ID: 35099351
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Isavuconazonium sulfate for the treatment of fungal infection.
    Walker RC; Zeuli JD; Temesgen Z
    Drugs Today (Barc); 2016 Jan; 52(1):7-16. PubMed ID: 26937491
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Pharmacoeconomic evaluation of isavuconazole, posaconazole, and voriconazole for the treatment of invasive mold diseases in hematological patients: initial therapy prior to pathogen differential diagnosis in China.
    Han G; Xu Q; Lv Q; Li X; Shi X
    Front Public Health; 2023; 11():1292162. PubMed ID: 38179563
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Isavuconazole: A new broad-spectrum azole. Part 1: In vitro activity.
    Denis J; Ledoux MP; Nivoix Y; Herbrecht R
    J Mycol Med; 2018 Mar; 28(1):8-14. PubMed ID: 29534853
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Part 2: mucormycosis: focus on therapy.
    Lynch JP; Zhanel GG
    Expert Rev Anti Infect Ther; 2023; 21(7):737-748. PubMed ID: 37300820
    [TBL] [Abstract][Full Text] [Related]  

  • 27. New triazoles and echinocandins: mode of action, in vitro activity and mechanisms of resistance.
    Fera MT; La Camera E; De Sarro A
    Expert Rev Anti Infect Ther; 2009 Oct; 7(8):981-98. PubMed ID: 19803707
    [TBL] [Abstract][Full Text] [Related]  

  • 28. New pharmacological opportunities for the treatment of invasive mould diseases.
    Ledoux MP; Toussaint E; Denis J; Herbrecht R
    J Antimicrob Chemother; 2017 Mar; 72(suppl_1):i48-i58. PubMed ID: 28355467
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Evaluation of the pharmacokinetics and clinical utility of isavuconazole for treatment of invasive fungal infections.
    Livermore J; Hope W
    Expert Opin Drug Metab Toxicol; 2012 Jun; 8(6):759-65. PubMed ID: 22530880
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Systemic antifungal therapy with isavuconazonium sulfate or other agents in adults with invasive mucormycosis or invasive aspergillosis (non-fumigatus): A multicentre, non-interventional registry study.
    Thompson GR; Garcia-Diaz J; Miceli MH; Nguyen MH; Ostrosky-Zeichner L; Young JH; Fisher CE; Clark NM; Greenberg RN; Spec A; Kovanda L; Croos-Dabrera R; Kontoyiannis DP
    Mycoses; 2022 Feb; 65(2):186-198. PubMed ID: 34888961
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Economic evaluation of isavuconazole for suspected invasive pulmonary aspergillosis in Canada.
    Beauchemin C; Guinan K; Claveau D; Dufresne SF; Rotstein C
    Expert Rev Pharmacoecon Outcomes Res; 2022 Jul; 22(5):805-814. PubMed ID: 34524935
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Real-World Use of Isavuconazole as Primary Therapy for Invasive Fungal Infections in High-Risk Patients with Hematologic Malignancy or Stem Cell Transplant.
    Dagher H; Hachem R; Chaftari AM; Jiang Y; Ali S; Deeba R; Shah S; Raad I
    J Fungi (Basel); 2022 Jan; 8(1):. PubMed ID: 35050014
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Isavuconazonium sulfate: a new agent for the treatment of invasive aspergillosis and invasive mucormycosis.
    Kovanda LL; Maher R; Hope WW
    Expert Rev Clin Pharmacol; 2016 Jul; 9(7):887-97. PubMed ID: 27160418
    [TBL] [Abstract][Full Text] [Related]  

  • 34. In vitro activities of isavuconazole and comparator antifungal agents tested against a global collection of opportunistic yeasts and molds.
    Pfaller MA; Messer SA; Rhomberg PR; Jones RN; Castanheira M
    J Clin Microbiol; 2013 Aug; 51(8):2608-16. PubMed ID: 23740727
    [TBL] [Abstract][Full Text] [Related]  

  • 35. The cost-effectiveness of isavuconazole compared to voriconazole, the standard of care in the treatment of patients with invasive mould diseases, prior to differential pathogen diagnosis in Spain.
    Azanza JR; Grau S; Vázquez L; Rebollo P; Peral C; López-Ibáñez de Aldecoa A; López-Gómez V
    Mycoses; 2021 Jan; 64(1):66-77. PubMed ID: 32989796
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Diagnosis and Treatment of Invasive Mold Diseases.
    Lee SO
    Infect Chemother; 2023 Mar; 55(1):10-21. PubMed ID: 36603818
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Liposomal amphotericin B: a review of its use as empirical therapy in febrile neutropenia and in the treatment of invasive fungal infections.
    Moen MD; Lyseng-Williamson KA; Scott LJ
    Drugs; 2009; 69(3):361-92. PubMed ID: 19275278
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Triazole antifungal agents in invasive fungal infections: a comparative review.
    Lass-Flörl C
    Drugs; 2011 Dec; 71(18):2405-19. PubMed ID: 22141384
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Isavuconazole for the Treatment of Invasive Mold Disease in Solid Organ Transplant Recipients: A Multicenter Study on Efficacy and Safety in Real-life Clinical Practice.
    Fernández-Ruiz M; Bodro M; Gutiérrez Martín I; Rodriguez-Álvarez R; Ruiz-Ruigómez M; Sabé N; López-Viñau T; Valerio M; Illaro A; Fortún J; Salto-Alejandre S; Cordero E; Fariñas MDC; Muñoz P; Vidal E; Carratalà J; Goikoetxea J; Ramos-Martínez A; Moreno A; Aguado JM;
    Transplantation; 2023 Mar; 107(3):762-773. PubMed ID: 36367924
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Broad spectrum triazoles for invasive mould infections in adults: Which drug and when?
    Jenks JD; Mehta SR; Hoenigl M
    Med Mycol; 2019 Apr; 57(Supplement_2):S168-S178. PubMed ID: 30816967
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 17.